

December 2003

Issue 15

Headlines:

- Major Funding Success
- Canadian Stroke Consortium approves ENOS
- Report of Data Monitoring Committee
- ENOS moves internet address
- Tip of the month
- Recruitment rate

ENOS milestones:

- 1st patient – 20/7/01
- 2nd site – 26/12/01
- Largest GTN trial (n=91) – 17/3/03
- Bigger than metanalysis (n=128) – 8/6/03

Recruitment total: 193

- Aberdeen - 21
- Bishop Auckland - 12
- Boston - 1
- Cheltenham - 0
- Halifax (Canada) - 6
- Liverpool - 3
- Mansfield - 0
- Manila - 0
- Nottingham (City) - 68
- Nottingham (QMC) - 0
- Sheffield (Hallamshire) - 1
- Singapore - 46
- Sydney (Canada) - 1
- Rhyl - 0
- Warsaw (IPN) - 30
- Warsaw (MMA) - 4

ENOS NEWS

The Newsletter for the 'Efficacy of Nitric Oxide in Stroke Trial'

Major Funding Success for ENOS

We are delighted to announce that BUPA Foundation, a UK-based charity, have agreed to fund the ENOS start-up phase for 2 years. The support is in addition to that received

from The Hypertension Trust last year and will cover central office costs and centre payments. The aim is to recruit 400 patient in the start up phase.

Canadian Stroke Consortium approves ENOS

Further important news - The Canadian Stroke Consortium, through its research and development committee, has approved the protocol in October and has recommended it to all Canadian

centres. This will enable further expansion of the trial in North America.

Report of Data Monitoring Committee

The data monitoring committee met on 4 November and reviewed data on 174 patients randomised by the end of October. In reviewing the

trial's data the committee "had no concerns and recommended that recruitment continue". The next review will be in March 2004.

ENOS moves internet address

All centres should note that ENOS now has its own internet address: www.enos.ac.uk. If you have book-marked the old address then please

make sure that you update your internet browser software to take account of this change.

Tip of the month

On the day 7 form there are a series of important questions about events that may occur during the 7 day treatment period, e.g. headaches, hypotension or stroke recurrence (see section A). We would like to clarify that these questions relate to events that have occurred

during the treatment phase of the trial only. An updated version of the day 7 form will soon be available which will make this clearer. Please note that if any of these events do occur on treatment then you should also consider submitting an SAE if appropriate.

Recruitment rate

The excellent news on funding, Canadian support and from the Data Monitoring Committee is a spur to increase our recruitment rate. Please consider all your acute stroke patients

for enrollment in ENOS

A merry Christmas and Happy New Year to all our readers.